StoneX Group’s Beam Therapeutics BEAM Stock Holding History

StoneX Group’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,992	Closed	-$256K	–	475
2021 Q2	$256K	Buy	+1,992	New	+$159K	0.04%	395

Other funds holding BEAM

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

StoneX Group's BEAM Position: Q3 2021 in Review

StoneX Group sold out of Beam Therapeutics (BEAM) in Q3 2021, closing a stake of 1,992 shares — an estimated $256K sold.

StoneX Group first reported a position in BEAM in Q2 2021 and held it in 1 quarter. The position peaked at $256K in Q2 2021. 231 funds tracked by Wall St. Rank hold BEAM as of Q3 2021.

StoneX Group reported no remaining Beam Therapeutics position as of Q3 2021 after selling out during the quarter.
StoneX Group sold 1,992 Beam Therapeutics shares in Q3 2021, an estimated $256K.
StoneX Group first reported a position in Beam Therapeutics in Q2 2021 and held it in 1 quarter.
StoneX Group's Beam Therapeutics position peaked at $256K in Q2 2021.
231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2021.

Based on StoneX Group's 13F filing for Q3 2021, filed 20 Oct 2021.